# A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

> **NCT06745531** · PHASE3 · COMPLETED · sponsor: **Taisho Pharmaceutical Co., Ltd.** · enrollment: 101 (actual)

## Conditions studied

- Hyperphosphatemia Patients on Hemodialysis

## Interventions

- **DRUG:** TS-172 20~60 mg/day
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06745531
- **Lead sponsor:** Taisho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-06
- **Primary completion:** 2025-10-13
- **Final completion:** 2025-10-20
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06745531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06745531, "A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06745531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*